Metrics to compare | NYR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNYRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.1x | −4.2x | −0.2x | |
PEG Ratio | 1.36 | −0.01 | 0.00 | |
Price/Book | 12.5x | 1.3x | 2.6x | |
Price / LTM Sales | 59.1x | 6.4x | 2.7x | |
Upside (Analyst Target) | - | 443.9% | 72.2% | |
Fair Value Upside | Unlock | 8.0% | 12.4% | Unlock |
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.